Clinical trial
An Open Label, Phase I/II Trial of Rituximab Therapy for Steroid-Refractory Chronic Graft vs. Host Disease
NCT00136396 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Phase I/II Trial of Rituximab Therapy for Steroid-Refractory Chronic Graft vs. Host Disease
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 31, 2004
- Completion date
- November 30, 2010
- Enrollment
- 30 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.